Single Center Experience on Abatacept and Late Acute Graft Versus Host Disease

Key Points

• Treatment response to abatacept improves symptoms of graft versus host disease, indicating its efficacy.
• Among the tested cases, significant improvement was noted in several patients treated with abatacept.
• Observational analysis of patients with late acute graft versus host disease highlights the immune suppression effects of therapy.
• Findings may support the use of abatacept as a viable option for managing late acute graft versus host disease.